Cytokines IL-1α, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression:: restoration by interferon γ

被引:36
作者
Thomas, GR
Chen, Z
Leukinova, E
Van Waes, C
Wen, J
机构
[1] Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA
[2] NIDCD, Tumor Biol Sect, NIH, Bethesda, MD USA
关键词
cytokines; IFN-gamma; CD80; squamous cell carcinoma; regulation;
D O I
10.1007/s00262-003-0433-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We previously characterized the expression of CD80 in different murine head and neck squamous cell carcinoma (HNSCC) clones derived following tumor progression in the absence of T cell-mediated immunity in severe combined immunodeficient (SCID) mice. We found that HNSCCs that did not express CD80 grew as progressors, while those that expressed CD80 were regressors when grown in immune-competent animals. In the present study, we characterized expression of a repertoire of immunoregulatory cytokines in these HNSCC lines, and found that HNSCCs that express cytokines IL-1alpha, IL-6, and GM-CSF do not express CD80, suggesting the hypothesis that these cytokines may down-modulate expression of CD80. Cytokine-conditioned medium from progressor HNSCC and recombinant IL-1alpha, IL-6, and GM-CSF caused a reduction of CD80 expression in regressor HNSCCs without affecting proliferation. Conversely, the decrease in CD80 expression in progressor HNSCCs could be restored by IFN-gamma, a known inducer of CD80 expression. These data strongly suggest that high levels of cytokines IL-1alpha, IL-6, and GM-CSF expressed by tumor cells can down-regulate CD80 expression in HNSCC, and that IFN-gamma can independently stimulate expression. These data provide evidence for a novel mechanism of cytokine-mediated down-modulation of CD80 during malignant progression of HNSCC that can be restored by IFN-gamma.
引用
收藏
页码:33 / 40
页数:8
相关论文
共 37 条
[1]  
BENNETT SH, 1971, CANCER, V28, P1255, DOI 10.1002/1097-0142(1971)28:5<1255::AID-CNCR2820280524>3.0.CO
[2]  
2-A
[3]   CYTOKINES AND CANCER - EXPERIMENTAL SYSTEMS [J].
BLANKENSTEIN, T ;
ROWLEY, DA ;
SCHREIBER, H .
CURRENT OPINION IN IMMUNOLOGY, 1991, 3 (05) :694-698
[4]  
BURKEY BB, 1991, ARCH OTOLARYNGOL, V117, P1281
[5]   ACTIVATION OF HUMAN DENDRITIC CELLS THROUGH CD40 CROSS-LINKING [J].
CAUX, C ;
MASSACRIER, C ;
VANBERVLIET, B ;
DUBOIS, B ;
VANKOOTEN, C ;
DURAND, I ;
BANCHEREAU, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 1994, 180 (04) :1263-1272
[6]   Co-stimulation in T cell responses [J].
Chambers, CA ;
Allison, JP .
CURRENT OPINION IN IMMUNOLOGY, 1997, 9 (03) :396-404
[7]  
Chen Z, 1999, CLIN CANCER RES, V5, P1369
[8]  
Cheng XF, 1998, J IMMUNOL, V160, P2735
[9]   CHARACTERIZATION OF CELLS FROM INVADED LYMPH-NODES IN PATIENTS WITH SOLID TUMORS - LYMPHOKINE REQUIREMENT FOR TUMOR-SPECIFIC LYMPHOPROLIFERATIVE RESPONSE [J].
COZZOLINO, F ;
TORCIA, M ;
CAROSSINO, AM ;
GIORDANI, R ;
SELLI, C ;
TALINI, G ;
REALI, E ;
NOVELLI, A ;
PISTOIA, V ;
FERRARINI, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1987, 166 (02) :303-318
[10]  
DEVITA VT, 1995, BIOL THERAQPY CANC